Latanoprost Patent Expiration
Latanoprost is Used for managing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first introduced by Upjohn Us 2 Llc
Latanoprost Patents
Given below is the list of patents protecting Latanoprost, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Iyuzeh | US8637054 | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives | Jul 08, 2031 | Thea Pharma |
| Xelpros | US9629852 | Ophthalmic composition comprising a prostaglandin | Sep 12, 2029 | Sun Pharm |
| Xelpros | US9539262 | Ophthalmic composition comprising a prostaglandin | Oct 15, 2028 | Sun Pharm |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Latanoprost's patents.
Latest Legal Activities on Latanoprost's Patents
Given below is the list recent legal activities going on the following patents of Latanoprost.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9539262 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Oct, 2020 | US9629852 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jul, 2020 | US9539262 |
| Recordation of Patent Grant Mailed Critical
| 25 Apr, 2017 | US9629852 |
| Patent Issue Date Used in PTA Calculation Critical
| 25 Apr, 2017 | US9629852 |
| Email Notification Critical
| 06 Apr, 2017 | US9629852 |
| Issue Notification Mailed Critical
| 05 Apr, 2017 | US9629852 |
| Dispatch to FDC | 17 Mar, 2017 | US9629852 |
| Application Is Considered Ready for Issue Critical
| 16 Mar, 2017 | US9629852 |
| Issue Fee Payment Verified Critical
| 13 Mar, 2017 | US9629852 |
Latanoprost's Family Patents
